CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
administering low dose rivaroxaban to reduce the risk of major adverse cardiac event (MACE) in people with Chronic Kidney Disease ...
Phase 3
Boulogne-Billancourt, France and 82 other locations
This study is open to adults with chronic kidney disease (CKD) that is at risk of getting worse. People who have taken a specific t ...
Phase 2
Le Kremlin-Bicêtre, France and 73 other locations
The KDOQI 2020 - Clinical practice guideline for nutrition in chronic kidney disease (CKD) -recommends protein restriction to reduc...
Paris, France and 20 other locations
and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney...
Phase 3
Paris, France and 642 other locations
This study will look if CagriSema can lower kidney damage in people with chronic kidney disease (CKD), type 2 diabetes (T2...
Phase 2
Paris Cedex 14, France and 122 other locations
tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney...
Phase 2, Phase 3
Paris, France and 312 other locations
Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney...
Phase 3
Paris, France and 154 other locations
Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney...
Phase 3
Paris, France and 157 other locations
with end stage kidney disease (ESKD) undergoing maintenance dialysis....
Phase 2, Phase 3
Paris, France and 250 other locations
of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/ ...
Phase 3
Paris, Île-de-France, France and 845 other locations
Clinical trials
Research sites
Resources
Legal